(FTLF) FitLife Brands Common - Ratings and Ratios

FitLife Brands, Inc. (NASDAQ:FTLF) is a leading developer and marketer of innovative, high-quality nutritional supplements and wellness products. The company serves health-conscious consumers globally, offering a diverse portfolio of products across weight loss, sports nutrition, general health, and male health categories. Its product lineup emphasizes natural, vegan, and organic formulations, catering to the growing demand for clean and sustainable wellness solutions. The company operates through a multi-brand strategy, marketing products under well-known brands such as NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals. These products are distributed through a combination of franchised stores, specialty retail locations, mass retailers, and online platforms. FitLife Brands, Inc. was formerly known as Bond Laboratories, Inc. and rebranded in September 2013. The company, incorporated in 2005, is headquartered in Omaha, Nebraska.

The company’s financial profile reflects its position in the growing nutritional supplements market. With a market capitalization of $160.39 million, FitLife Brands demonstrates moderate scale within the personal care products industry. Its price-to-earnings (P/E) ratio of 21.53 indicates a premium valuation relative to its current earnings, while the forward P/E of 13.77 suggests investor expectations for improved profitability. The price-to-book (P/B) ratio of 4.09 highlights a significant gap between market value and book value, potentially reflecting intangible assets or growth prospects. The price-to-sales (P/S) ratio of 2.27 aligns with industry averages for consumer goods companies. Return on equity (RoE) of 24.57% underscores strong profitability relative to shareholder equity.

From a technical perspective, FTLF stock has shown stability in recent trading sessions, with a 20-day average volume of 14,951 shares. The stock price of $14.94 is slightly below its 20-day SMA of $15.18 but remains close to its 50-day SMA of $15.57 and 200-day SMA of $15.88. The average true range (ATR) of 1.23 reflects moderate volatility, suggesting potential for near-term price fluctuations within a narrow range.

3-Month Forecast: Based on and , FTLF is expected to trade sideways to slightly upward in the near term, with resistance near the 50-day and 200-day SMAs. The stock’s valuation multiples, particularly the forward P/E, suggest investor optimism about future earnings growth. However, the premium valuation relative to book value may limit upside potential unless driven by strong earnings surprises. The moderate ATR indicates manageable volatility, making the stock suitable for risk-averse investors seeking exposure to the nutritional supplements sector.